Fingolimod recommended by NICE as an option for MS

NICE has approved fingolimod (Gilenya), the first oral treatment for patients with highly active relapsing-remitting multiple sclerosis.

Gilenya (fingolimod) was rejected by the SMC earlier this year
Gilenya (fingolimod) was rejected by the SMC earlier this year
Fingolimod (Gilenya), the first licensed sphingosine 1-phosphate receptor modulator, may be prescribed on the NHS for patients with an unchanged or increased relapse rate or ongoing severe relapses compared with the previous year despite treatment with interferon beta. However, the manufacturer must provide fingolimod with the discount agreed as part of the patient access scheme.

Safety concerns

The MHRA recently published updated monitoring advice for fingolimod following reports of sudden cardiac death after the initial dose.

Guidance summary

NICE guidance on fingolimod

Further information

View Gilenya drug record

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases